SAN DIEGO--(BUSINESS WIRE)--April 28, 2006--AVANIR Pharmaceuticals (NASDAQ:AVNR - News) announced today that results of a pivotal Phase III clinical trial evaluating Neurodex(TM) for the treatment of patients with involuntary emotional expression disorder (IEED), also known as pseudobulbar affect and emotional lability, were published for the first time in the May issue of Annals of Neurology (Vol 59, Issue 5, 2006, pp 780-787). Data from this trial were previously presented at U.S. and international medical meetings in 2005. The published article "Randomized, Controlled Trial of Dextromethorphan/Quinidine for Pseudobulbar Affect in Multiple Sclerosis" describes the safety and efficacy of Neurodex, an orally administered combination of dextromethorphan and low dose quinidine, in the treatment of IEED patients with multiple sclerosis (MS).
